DE-130A (Latanoprost) Emerging Drug Insight

“DE-130A (Latanoprost), Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about DE-130A (Latanoprost) for Glaucoma in the 6MM (EU5 and Japan). A detailed picture of the DE-130A (Latanoprost)  for Glaucoma in the 6MM, i.e., EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the DE-130A (Latanoprost)  for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DE-130A (Latanoprost) market forecast, analysis for Glaucoma in the 6MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

Drug Summary

DE-130A is an ophthalmic emulsion of a prostaglandin F2α derivative for the treatment of glaucoma and ocular hypertension. This product is in Phase III clinical development stage. Santen has been conducting phase III trials since April 2019 in Europe and Asia.

DE-130A is preservative-free latanoprost 50μg/mL presented in a lipid-containing cationic emulsion, a technology in which the positively-charged emulsion droplets are attracted onto the negatively charged ocular surface to increase their spreading and residence time on the ocular surface. 5 This patented cationic emulsion technology, developed by Santen, improves the tear film lipid layer surface properties; it is used as the core technology for other marketed products in more than 30 countries, including in artificial tears for dry eye disease. Latanoprost, the most commonly prescribed prostaglandin analogue in Europe, lowers elevated IOP7.

In October 2022, Santen Pharmaceutical announced the European Medicines Agency (EMA) has accepted for review the marketing authorization application for the use of STN1013001 (DE-130A) for lowering intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the DE-130A (Latanoprost) description, mechanism of action, dosage and administration, research and development activities in Glaucoma.
•  Elaborated details on DE-130A (Latanoprost) regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the DE-130A (Latanoprost) research and development activity in Glaucoma in detail across the Europe and Japan.
•  The report also covers the patents information with expiry timeline around DE-130A (Latanoprost).
•  The report contains forecasted sales of DE-130A (Latanoprost) for Glaucoma till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Glaucoma.
•  The report also features the SWOT analysis with analyst views for DE-130A (Latanoprost) in Glaucoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DE-130A (Latanoprost) Analytical Perspective by DelveInsight

• In-depth DE-130A (Latanoprost)  Market Assessment

This report provides a detailed market assessment of DE-130A (Latanoprost) in Glaucoma in the 6MM, i.e., EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

• DE-130A (Latanoprost)  Clinical Assessment

The report provides the clinical trials information of DE-130A (Latanoprost) in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DE-130A (Latanoprost) dominance.
•  Other emerging products for Glaucoma are expected to give tough market competition to DE-130A (Latanoprost) and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DE-130A (Latanoprost) in Glaucoma.
•  Our in-depth analysis of the forecasted sales data of DE-130A (Latanoprost) from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DE-130A (Latanoprost) in Glaucoma.

Key Questions

•  What is the product type, route of administration and mechanism of action of DE-130A (Latanoprost)?
•  What is the clinical trial status of the study related to DE-130A (Latanoprost) in Glaucoma and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DE-130A (Latanoprost) development?
•  What are the key designations that have been granted to DE-130A (Latanoprost) for Glaucoma?
•  What is the forecasted market scenario of DE-130A (Latanoprost) for Glaucoma?
•  What are the forecasted sales of DE-130A (Latanoprost) in the six major countries, including the Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Glaucoma and how are they giving competition to DE-130A (Latanoprost) for Glaucoma?
•  Which are the late-stage emerging therapies under development for the treatment of Glaucoma?